HomeCompareCTYLF vs ABBV

CTYLF vs ABBV: Dividend Comparison 2026

CTYLF yields 3.05% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $82.1K in total portfolio value
10 years
CTYLF
CTYLF
● Live price
3.05%
Share price
$0.33
Annual div
$0.01
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.2K
Annual income
$0.31
Full CTYLF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — CTYLF vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCTYLFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CTYLF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CTYLF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CTYLF
Annual income on $10K today (after 15% tax)
$259.34/yr
After 10yr DRIP, annual income (after tax)
$0.26/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $21,055.74/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CTYLF + ABBV for your $10,000?

CTYLF: 50%ABBV: 50%
100% ABBV50/50100% CTYLF
Portfolio after 10yr
$61.3K
Annual income
$12,386.03/yr
Blended yield
20.22%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

CTYLF
No analyst data
Altman Z
3.4
Piotroski
7/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CTYLF buys
0
ABBV buys
0
No recent congressional trades found for CTYLF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCTYLFABBV
Forward yield3.05%3.06%
Annual dividend / share$0.01$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%40.6%
Portfolio after 10y$20.2K$102.3K
Annual income after 10y$0.31$24,771.77
Total dividends collected$308.00$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CTYLF vs ABBV ($10,000, DRIP)

YearCTYLF PortfolioCTYLF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$10,853$152.56$11,550$430.00$697.00ABBV
2$11,690$77.37$13,472$627.96$1.8KABBV
3$12,547$38.94$15,906$926.08$3.4KABBV
4$13,445$19.53$19,071$1,382.55$5.6KABBV
5$14,396$9.78$23,302$2,095.81$8.9KABBV
6$15,408$4.89$29,150$3,237.93$13.7KABBV
7$16,489$2.45$37,536$5,121.41$21.0KABBV
8$17,645$1.22$50,079$8,338.38$32.4KABBV
9$18,880$0.61$69,753$14,065.80$50.9KABBV
10$20,202$0.31$102,337$24,771.77$82.1KABBV

CTYLF vs ABBV: Complete Analysis 2026

CTYLFStock

City Lodge Hotels Limited operates hotels in South Africa and internationally. The company operates hotels under the Courtyard, City Lodge, Fairview, Town Lodge, and Road Lodge brands. It operates 1 Fairview hotel with 127 rooms; 5 Courtyard hotels with 480 rooms; 21 City Lodge hotels with 3,600 rooms; 13 Town Lodge hotels with 1,591 rooms; and 23 Road Lodge hotels with 2,272 rooms. The company was founded in 1985 and is headquartered in Bryanston, South Africa.

Full CTYLF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this CTYLF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CTYLF vs SCHDCTYLF vs JEPICTYLF vs OCTYLF vs KOCTYLF vs MAINCTYLF vs JNJCTYLF vs MRKCTYLF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.